A Study to Evaluate ALN-6222 in Participants With Obesity

Summary

This is a first in human, randomized, double-blind (DB), placebo-controlled, single ascending dose (SAD), Phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of ALN-6222 administered subcutaneously (SC) in adult participants with obesity.

Timeline

Start

2026-06-04

Primary completion

2027-12-14

Completion

2027-12-14

Drugs

Indications